| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| 25mg | |||
| 50mg | |||
| Other Sizes |
| Targets |
VI-16832 targets a broad spectrum of Type I kinases. It is a type I kinase inhibitor that binds to the ATP-binding site of kinases in their active conformation. It has been used to analyze more than 170 protein kinases in SILAC-labeled cancer cell lines, providing a versatile experimental tool for kinase signaling and pharmacological research.
|
|---|---|
| ln Vitro |
VI 16832 is a type I kinase inhibitor with a broad spectrum [1]. More than 8500 phosphopeptides were found by phosphoproteomic analysis of VI 16832-enriched fractions in MV4-11, HCT116, or 435S cells. These correspond to 212 distinct protein kinase superfamily members, or around 1700 distinct phosphopeptide compounds. The overall number of discovered phosphorylation sites on protein kinases was greatly increased by analysis of VI 16832 retained proteins from three cancer cell lines. When calculating the total phosphopeptide intensities to determine the quantity of protein enriched in VI 16832, protein kinases accounted for more than 80% of the total [2].
In vitro, VI-16832 is a broad-spectrum Type I kinase inhibitor. It has been used as an enrichment tool for phosphoproteomic analysis, resulting in more than 8500 phosphopeptide identifications from VI-16832-enriched fractions in MV4-11, HCT116, or 435S cells. It can be used for comparative expression analysis of protein kinases in different cancer cell lines. |
| ln Vivo |
In vivo activity data for VI-16832 are limited, as it is primarily used as a research tool for in vitro kinase enrichment and analysis rather than as a therapeutic compound. Its utility lies in its ability to enrich and identify kinases from cell lysates for proteomic studies.
|
| Enzyme Assay |
In vitro kinase binding assays for VI-16832 are performed using immobilized VI-16832 as an affinity matrix. Cell lysates are incubated with the immobilized compound, and bound kinases are eluted and identified by mass spectrometry. This approach enables the profiling of kinase expression and abundance across different cell lines.
|
| Cell Assay |
In vitro cellular assays for VI-16832 involve its use as an enrichment tool for kinase proteomics. Cells are lysed, and the lysate is incubated with VI-16832-conjugated beads. Bound proteins are eluted and analyzed by mass spectrometry to identify and quantify kinases. This allows for comparative expression analysis of protein kinases in different cancer cell lines.
|
| Animal Protocol |
In vivo animal experiments for VI-16832 are not applicable, as it is used as a research tool for in vitro proteomic analysis rather than as a therapeutic compound.
|
| ADME/Pharmacokinetics |
VI-16832 has a molecular weight of 391.47 and molecular formula C₂₂H₂₅N₅O₂. Its chemical name is 2-[4-(2-Aminoethoxy)anilino]-8-(2-bicyclo[2.2.1]heptanyl)pyrido[2,3-d]pyrimidin-7-one. It has a purity of 99.09%.
|
| Toxicity/Toxicokinetics |
Toxicological data for VI-16832 are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
VI-16832 is a broad-spectrum Type I kinase inhibitor used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines. It enables quantitative assessment of kinase relative abundance. This product is for research use only.
|
| Molecular Formula |
C22H25N5O2
|
|---|---|
| Molecular Weight |
391.466204404831
|
| Exact Mass |
391.2
|
| CAS # |
1430218-51-1
|
| PubChem CID |
89510076
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
611.9±65.0 °C at 760 mmHg
|
| Flash Point |
323.9±34.3 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.679
|
| LogP |
1.87
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
620
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC2CC1CC2N3C(=O)C=CC4=CN=C(N=C43)NC5=CC=C(C=C5)OCCN
|
| InChi Key |
RCSLGYIVHUXZCI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H25N5O2/c23-9-10-29-18-6-4-17(5-7-18)25-22-24-13-16-3-8-20(28)27(21(16)26-22)19-12-14-1-2-15(19)11-14/h3-8,13-15,19H,1-2,9-12,23H2,(H,24,25,26)
|
| Chemical Name |
2-[4-(2-Aminoethoxy)anilino]-8-(3-bicyclo[2.2.1]heptanyl)pyrido[2,3-d]pyrimidin-7-one
|
| Synonyms |
VI16832 VI 16832 VI-16832
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~85.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5545 mL | 12.7724 mL | 25.5447 mL | |
| 5 mM | 0.5109 mL | 2.5545 mL | 5.1089 mL | |
| 10 mM | 0.2554 mL | 1.2772 mL | 2.5545 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
